US-based multi-specialty health care company Allergan, the maker of Botox® and the Juvederm™ family of dermal fillers, has launched its next-generation hyaluronic acid (HA) dermal filler formulation, Juvederm™ XC in India. Juvederm™ XC contains the local anesthetic lidocaine to provide patients with enhanced comfort during treatment.
“As a physician, my priority is to ensure the best outcomes for my patients, as well as their comfort level during the injection. Previously it often took up to 30 minutes for an anesthetic block to take effect and an almost similar amount of time to reassure the patient. Now, with Juvederm™ XC, patients can enjoy a more comfortable injection experience and possibly less time in the clinic. Its formulation with 0.3 percent preservative-free lidocaine numbs the treatment area within seconds, potentially reducing the need for an additional anesthetic. Patients can receive the same smooth, long-lasting and natural-looking results demonstrated with existing formulations of Juvederm™,” said Dr Jamuna Pai, Cosmetologist, Blush.
While launching the new product, Diana Hayden added, “Today, feeling good is about looking good and this requires effort. Thanks to revolutionary products such as Juvederm™ XC, people have better options to restore their youthful looks in a more relaxed and comfortable manner.”
Approved by the U.S. Food and Drug Administration (FDA) in January 2010, Juvederm™ XC is the first and only smooth-consistency HA dermal filler formulated with lidocaine to smoothen the “parentheses” – facial wrinkles around the nose and mouth.